| INTRODUCTION

Hepatitis C virus (HCV) infection is a major global health burden
with an estimate of 71.1 million people affected by the disease worldwide. 1 HCV is the leading cause of cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC) in the West with many patients remaining undiagnosed until their presentation with symptoms of end-stage liver disease. 2 There has been an increasing trend in the number of HCV-related deaths in the USA documented between 2003 and 2013. 3 Since 1973, HCC incidence in the USA has increased from 1.5 cases per 100 000 person-years to 6.2 cases per 100 000 in 2011, and the incidence of HCC and hepatic decompensation are projected as continuing to increase. 4, 5 In the USA, racial disparities in the prevalence of HCV infection have been previously documented. Cross-sectional data from the National
Health and Nutrition Examination Survey (NHANES) studies from 1988
to 1994 and 1999 to 2002 reported African Americans having two times the prevalence of antibodies to HCV compared to non-Hispanic Caucasians. 6, 7 Among US military recruits, 1.8% of African Americans had HCV seropositivity compared to 0.1% in Caucasians, and in the US correctional population racial and ethnic minorities comprised a substantial proportion of the HCV burden. 8, 9 On screening studies in Asian American communities, HCV prevalence ranged from 2.2% to 6%, much higher than the estimated 1.6% overall prevalence in the USA. 7, [10] [11] [12] [13] [14] [15] [16] [17] Racial disparities in the outcomes of patients infected with chronic hepatitis C (CHC) have also been seen in the USA. 18 In a study of US veterans with CHC, Hispanic patients were found to have a higher cumulative incidence of cirrhosis and HCC compared to Caucasian patients. 19 Hispanic patients have also been shown to have higher all-cause mortality rates compared to non-Hispanic Caucasians and non-Hispanic African
Americans. 20 In a case-controlled study, Asian patients with HCV-related cirrhosis have been found to have a higher risk of developing HCC than Caucasian patients. 21, 22 Currently, the number of studies in the USA documenting the natural history for CHC patients with a well-characterised cohort with diverse ethnic representation are still limited.
The sustained virological response (SVR) is the desired endpoint of anti-viral therapy for CHC and is a marker for durable, virological cure of infection for the majority of patients. 23, 24 SVR is known to reduce the risk of progression to HCC and liver-related mortality, however, it is unclear if the effect would be similar among different ethnic groups and whether SVR could eliminate ethnic disparities in HCC, cirrhosis and its complications. 23, 25, 26 Our study seeks to evaluate ethnic differences in the natural history of HCV infection, quantify the rates of progression to cirrhosis, hepatic decompensation and HCC in a large, ethnically diverse cohort of CHC patients and to determine the impact of SVR on these rates.
2 | ME TH ODS
| Study design and patient population
We conducted a retrospective cohort study of 9,513 consecutive adult CHC patients seen at Stanford University Medical Center 
| Study outcomes
| Statistical analysis
Categorical variables were described using proportions (%) and evaluated using the chi-square (v   2   ) test. Continuous variables were described as meanAESD or median (interquartile range [IQR] ) and evaluated using ANOVA tests if normal distribution was observed.
Nonparametric tests were applied when assumptions of normality were not met. The Kaplan-Meier method was used to determine the Asians (0.1%) were in the minority (Table S1 ). There were also significant differences in clinical laboratory characteristics at presentation among the ethnic groups ( coinfection, failure to achieve SVR with anti-viral therapy or lack of therapy, and reduced platelet counts (Table 3) .
| Hepatic decompensation
In patients with prevalent cirrhosis at presentation, 270 developed symptoms of hepatic decompensation during follow-up. Crude incidence rates were similar between Asian (117. Significance determined using one-way ANOVA on ranks testing. On the other hand, without SVR, the ethnic disparity persisted.
As shown in Figure S1A -D, there was no significant difference in rates of cirrhosis or HCC development among the different ethnic groups, while the differences were clear and significant for both cirrhosis and HCC development. Similarly, while a significant difference in overall survival was observed between the ethnicities overall, the differences were eliminated once SVR was achieved (Figure 2A,B) .
As shown in 
| DISCUSSION
In this large, diverse cohort of patients with CHC, we found and confirmed that ethnic disparities exist in the progression to advanced liver disease for patients of four different ethnic groups. Hispanic and Asian ethnicities were found to be independently associated with greater risk of cirrhosis and HCC compared to Caucasian patients, while African Americans had a lower risk for both cirrhosis and HCC as well as a lower risk for hepatic decompensation in those with cirrhosis at presentation. Most importantly, our study demonstrated that in patients who achieved SVR, the ethnic disparity for increased risk of progression to cirrhosis and HCC seen in Hispanic and Asian patients no longer existed, suggesting that successful treatment with HCV eradication can eliminate the ethnic disparity and higher risk of cirrhosis and HCC that affect Asian and Hispanic CHC patients. In addition, the ethnic disparity in overall survival was also eliminated with successful SVR.
Between the years 2000 and 2010, Asians were the fastest growing racial group in the USA, demonstrating a 43% increase in population during this period. 29 In the West, there is a growing disease burden of chronic viral hepatitis in communities of immigrants who migrated from areas of high HCV prevalence and 60% of Asian population growth is from international migration, 30, 31 as most of our cohort (97.2%) of Asian patients were foreign-born. Globally, 80% of HCC cases occur in sub-Saharan Africa, East and Southeast Asia, with an incidence rate of over 20/100 000 person-years due to the high prevalence of chronic hepatitis B and CHC. 32, 33 In Asia, Malaysia and Singapore had the lowest number of HCC cases attributed to CHC, ranging from 2% to 2.4%, while Japan has the highest proportion of HCV-related HCC at 69.6%. 34 The HCC incidence rate seen in Asian patients from our cohort was 30.2/1000 person-years.
This incidence rate falls within the range seen in Asia, from 302.6/ 100 000 person-years in a study of 12 008 men in Taiwan to 5.8/ 100 person-years in South Korea. 35, 36 The finding in this cohort study that Asian CHC patients are at higher risk than Caucasian patients for developing HCC confirms findings from a previous casecontrolled study. 21 In addition to a higher risk for HCC, Asian patients were also more likely to be coinfected with HBV, further increasing the risk of developing HCC, and this factor was adjusted for in our multivariate model. 37, 38 An additional factor that may contribute to Asians having a higher risk of cirrhosis and HCC is the duration of infection. Many Asian CHC patients acquire the infection through iatrogenic exposure or unidentifiable risk factors and may have been infected for much longer than patients of other ethnic groups. 11, [39] [40] [41] This factor unfortunately could not be accounted for in our study since the majority of Asian patients with CHC could not recall a specific exposure in both retrospective and prospective studies. 39, 40 Our study also confirmed that Hispanic ethnicity is independently associated with higher risk of cirrhosis and HCC as previously seen in a large cohort of US veterans with CHC. 19 In this study by
El-Serag et al., the risk of cirrhosis in Hispanic patients was 28% 
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greater and the risk of HCC was 61% greater than Caucasian patients. 19 Hispanic patients from our cohort were found to have an even greater estimated risk-37% increased risk of cirrhosis and 47% increased risk of HCC compared to Caucasian patients. A previous, single-centre study from Los Angeles also found that Hispanic CHC patients had more rapid progression to fibrosis, with a higher fibrosis stage and greater degree of hepatic necroinflammation at index biopsy. 42 At presentation, 57.8% of Hispanic patients in our cohort presented with cirrhosis and 44.5% presented with symptoms of hepatic decompensation, which may also suggest a weaker linkage to care and, consequently, delayed diagnoses in this group.
In previous studies, African American patients were found to have a slower progression to fibrosis with lower fibrosis scores compared to Caucasian patients, and African American ethnicity being an independent factor associated with mild liver fibrosis. [43] [44] [45] Our study found that African American patients have the lowest incidence rates of cirrhosis, HCC and hepatic decompensation compared to other racial groups. El-Serag et al. also found that African American patients demonstrated the lowest progression rates to cirrhosis and HCC and a reduced risk of progressing to advanced liver disease compared to Caucasian patients. 19 Although the rates for African
American patients in our cohort were the lowest of the four ethnic groups, they were much higher than those found by El-Serag et al.,
with the rate to cirrhosis in our cohort being 39.3/1000 personyears vs 13.3/1000 person-years, and the rate to HCC being 6.7/ 1000 person-years vs 3.9/1000 person-years respectively. Although
African American patients were found to have a reduced risk of liver disease progression, we were unable to determine whether the ethnic disparity between African American and Caucasian patients could be resolved by SVR, due to limited follow-up time and the small number of African American patients in our cohort. With a larger cohort and longer duration of follow-up, the effect of an SVR on the ethnic disparity between African American and Caucasian patients in progression to advanced liver disease might be determined.
In patients with HCV infection, socioeconomic factors have been postulated to have a role in access to care. [46] [47] [48] Non-Caucasian ethnicity has been found to be independently associated with lack of insurance in patients with HCV infection. 47 In the presence of a known risk factor, Hispanics and African Americans were less likely to receive HCV testing compared to Caucasians and less than half of all ethnic minority HCV patients were referred for subspecialty care or treatment. 15, 48 Cultural, economic and insurance barriers faced by ethnic minorities result in poorer access to care and should be addressed in order to eliminate ethnic disparities in HCV outcomes.
Our study is limited by its retrospective study design with a cohort spanning 19 years, thus our results could potentially be affected by changes in patient cohort and practice pattern during this long period. Despite being limited by its observational and retrospective nature, the findings of our study are consistent with results seen in previous studies. To our knowledge, the current study is the first to show that the higher risk of cirrhosis and HCC in Hispanic and Asian CHC patients can be alleviated with successful treatment with anti-viral therapy, and that this risk may be modifiable with appropriate screening, diagnosis, and linkage to care of at-risk patients. In addition, the ethnic diversity in our cohort gave us an opportunity to describe the natural history of CHC in Asian American patients, a population that had not been well-characterised previously. However, the majority of our Asian patients were foreign-born, thus the same conclusions regarding increased cirrhosis and HCC risk might differ for American-born Asian patients.
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